GC-101 is under clinical development by Shanghai Gencells Therapeutics and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GC-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GC-101 overview
GC-101 is under development for the treatment of gastrointestinal tumors, epidermolysis bullosa, advanced solid tumors, metastasized breast cancer, glioma, advanced melanoma, hepatobiliary cancer, cervical cancer, head and neck squamous cell tumors, non-small cell lung cancer, breast cancer and pancreatic cancer. It is administered through parenteral and intravenous route. The therapy comprises of autologous tumor infiltrating lymphocytes (TILs).
Shanghai Gencells Therapeutics overview
Shanghai Gencells Therapeutics is a clinical-stage cell therapy platform company. It is headquartered in Shanghai, China.
For a complete picture of GC-101’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
